logo
This company wants to replace your Pap smear — and promises its DIY cancer screening is less painful

This company wants to replace your Pap smear — and promises its DIY cancer screening is less painful

New York Post12-05-2025
Short of shopping for a bikini after the holidays, getting a Pap smear has to be one of the most dreaded parts of a woman's life.
Now, a new device — which was recently approved by the FDA — promises to be the first at-home test for cervical cancer screening.
And, according to Teal Health co-founder and CEO Kara Egan, the Teal Wand will revolutionize the way women approach pelvic exams.
4 The Teal Wand promises to be the first at-home test for cervical cancer screening.
Teal Health
'Generally, no one enjoys going to the OBGYN for a routine pap smear,' Egan told The Post.
'Between the uncomfortable stirrups, the paper gown, and the cold, metal speculum, it's usually an unpleasant experience many women avoid.
'In fact, 1 in 4 women aren't regularly screened due to access issues or discomfort with traditional exams. With this in mind, we set out to change the experience entirely, and offer a comfortable at-home option to test for cervical cancer.'
Egan also noted that Pap smears aren't even 'the recommended way of screening' anymore, with modern medicine preferring the HPV test 'because of its sensitivity and accuracy.'
The Teal Wand looks a bit like a tampon applicator, with a soft sponge tip that collects cervical cells for HPV testing.
To use it, women request a kit online, get approved by a Teal Health provider and receive the device in the mail.
4 Egan also noted that pap smears aren't even 'the recommended way of screening' anymore, with modern medicine preferring the HPV test 'because of its sensitivity and accuracy.'
Iryna – stock.adobe.com
After a quick self-collection at home — Egan said 92% of users finished in under five minutes — the sample is sealed and sent to a CLIA-certified lab for analysis.
Results are then reviewed by certified doctors and users can connect with Teal's virtual care team to discuss any next steps.
Each year in the US, about 11,500 new cases of cervical cancer are diagnosed and about 4,000 women die from it, according to the CDC.
Cervical cancer is one of the most preventable cancers — if it's caught early through regular screening.
But so many women put off or skin their Paps altogether, dreading their recommended annual gynecological exam — and the at times painful scraping of the small brush used to collect the sample from the cervic.
4 To use the Teal Wand, women request a kit online, get approved by a Teal Health provider, and receive the device in the mail.
Teal Health
'Pain and discomfort with the in-office speculum exam are some of the top reasons women are behind on their screening,' Egan said.
'Other reasons include anything from living in OBGYN care deserts, to medical anxiety or sexual trauma, to not having enough time to prioritize their health over their family priorities.'
With the Teal Wand, they are hoping to put the power back into women's hands — literally.
'That's why we created the Teal Wand — to give women the option to screen comfortably from home at their convenience,' she said.
The wand is single-use and Egan noted that it 'will be covered by insurance, with out-of-pocket and HSA/FSA payment options to ensure it is affordable and accessible for all women.'
4 Women collect samples at home and send them to a certified lab for testing.
Teal Health/AFP via Getty Images
And when it comes to effectiveness — the numbers are solid, according to Egan.
'In a clinical trial, it found that Teal Wand's clinical sensitivity is 96%, matching the performance of clinician-collected samples,' she said. 'Self-collected samples had an agreement of 95% with clinician-collected samples, surpassing the threshold for equivalency.'
Women seem to get the hang of it quickly as well — 99% reported no difficulty using the device and 98% of samples were valid for lab analysis.
The new device was just approved by the FDA on Friday. Their decision was based on a study of more than 600 women, which found that their at-home samples performed as well as ones collected by doctors.
While the price of the new wand hasn't been disclosed, the company said it is working with insurance providers for coverage and flexible payment options.
They expect to begin selling test to people age 25 to 65 in June.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Yahoo

time28 minutes ago

  • Yahoo

Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California

Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging

Americans' faith in food safety plummets
Americans' faith in food safety plummets

Yahoo

timean hour ago

  • Yahoo

Americans' faith in food safety plummets

Over the past several months, the federal government has made extensive cuts to instrumental food health and safety organizations like the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Center for Disease Control. And now, Gallup polling released this week says American confidence in the government to ensure food safety is at a new low. Shocker. Only 53% of Americans say they have a 'great deal' or 'fair amount' of confidence in food safety. This number has been dropping since 2006, however, there was a sharp decline starting in 2019. Despite this, 84% of Americans still report that their diet is at least 'somewhat healthy,' a number that has stayed consistent since Gallup started this reporting in 2001, but there hasn't been much — if any — increase in how many people are paying attention to nutrition labels and food warnings. Something that has become increasingly necessary as new food recalls are being announced almost daily. The USDA and FDA release public notices when they become aware of a recall, however, some of these notices aren't released until weeks or months after a contamination was reported. These recalls aren't always the easiest to find, sometimes they're hiding in the FDA Enforcement Report, which is completely different from the Recall, Market Withdrawals, & Safety Alerts Data Base. For example, in this week's enforcement report there are six ongoing recalls from the same company (King Cheesecake Company Inc.) because various products included pecans that were potentially contaminated with salmonella. This is listed as a Class I recall, the most serious from the FDA. The recall was initiated on July 18, but not classified by the FDA until August 7. To make matters worse, there is no listed press release for the recall even though it affects products and consumers in six different states including Alabama, Texas, Florida, Louisiana, Oklahoma and Illinois. Despite the cuts, officials have maintained that the number of inspectors and other food regulators will not change. Other experts are saying these cuts are a massive threat to public health and safety and could lead to dangerous disease outbreaks and consistent food recalls. Who's to say which is true, but it's clear the majority of Americans aren't confident in our food systems right now. All in the name of making America healthy again — apparently. The post Americans' faith in food safety plummets appeared first on Solve the daily Crossword

What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?

Yahoo

time2 hours ago

  • Yahoo

What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?

Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store